Finerenone Benefits Patients With T2D and CKD No Matter What Edited by Devyani Gholap Medscape UK May 07, 2026

https://www.medscape.com/viewarticle/finerenone-benefits-patients-t2d-and-ckd-no-matter-what-2026a1000eg3 Among patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), those who met more American Diabetes Association (ADA)-recommended treatment goals at baseline had a lower risk for adverse cardiovascular (CV) and kidney events. Finerenone reduced these risks compared with placebo, regardless of the number of treatment goals met at baseline.